Kangmei Pharmaceutical Co Ltd (600518.SS)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|46||1997||Chairman of the Board, General Manager|
|45||1997||Vice Chairman of the Board, Deputy General Manager|
|43||2001||Chief Financial Officer|
|55||2008||Deputy General Manager|
|48||2017||Deputy General Manager|
- BRIEF-Kangmei Pharmaceutical obtains high-tech enterprise recognition again and to enjoy tax preference
- BRIEF-Kangmei Pharmaceutical Says Q1 Net Profit Up 33.3 Percent Y/Y
- BRIEF-Kangmei Pharmaceutical to pay annual cash div as 2.35 yuan per 10 shares for FY 2017
- BRIEF-Kangmei Pharmaceutical's 2017 Net Profit Up 22.8 Pct Y/Y At 4.1 Bln Yuan
- BRIEF-Kangmei Pharmaceutical Plans Debt Financing Instruments And Bonds, To Invest In Zhuhai Headquarters